Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Amortization of Deferred Charges (2020 - 2025)

Syndax Pharmaceuticals (SNDX) has 5 years of Amortization of Deferred Charges data on record, last reported at -$1000.0 in Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges fell 103.33% year-over-year to -$1000.0; the TTM value through Dec 2025 reached $228000.0, up 660.0%, while the annual FY2025 figure was $228000.0, 660.0% up from the prior year.
  • Amortization of Deferred Charges reached -$1000.0 in Q4 2025 per SNDX's latest filing, down from $62000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $792000.0 in Q3 2022 and bottomed at -$1.1 million in Q4 2022.
  • Average Amortization of Deferred Charges over 4 years is $51333.3, with a median of $113000.0 recorded in 2021.
  • Peak YoY movement for Amortization of Deferred Charges: surged 538.71% in 2022, then plummeted 103.33% in 2025.
  • A 4-year view of Amortization of Deferred Charges shows it stood at $124000.0 in 2021, then tumbled by 989.52% to -$1.1 million in 2022, then surged by 102.72% to $30000.0 in 2024, then crashed by 103.33% to -$1000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were -$1000.0 in Q4 2025, $62000.0 in Q3 2025, and $55000.0 in Q2 2025.